Debiopharm is a privately-held Swiss biopharmaceutical company mainly active in development and clinical testing of drug candidates. It was founded in...
19 KB (1,557 words) - 09:08, 2 October 2024
developed by Debiopharm, is launched in two European countries - a new therapeutic avenue for the treatment of sexual deviations". Debiopharm. 23 June 2009...
14 KB (981 words) - 11:38, 23 March 2024
Retrieved 7 October 2020. "Debiopharm Group™ presents the 'Debiopharm Group Life Sciences Award 2013' and two 'Junior Debiopharm Group Life Sciences Awards...
15 KB (1,219 words) - 16:20, 19 September 2024
Daiichi Sankyo (2005– ) Danco (2000– ) Darou Pakhsh (1956– ) Dawa (1994– ) Debiopharm (1979– ) Dechra (1997- ) Delix (2019– ) Dentsply Sirona (1899– ) Dermapharm...
34 KB (2,178 words) - 14:38, 14 November 2024
Afabicin (Debio 1450) is an experimental antibiotic developed by Debiopharm for the treatment of Staphylococcus aureus infections. It is a prodrug which...
4 KB (357 words) - 00:34, 18 October 2024
headquarters Cochlear Limited Basel Basel-Stadt European headquarters Debiopharm Lausanne Vaud Global headquarters Edwards Lifesciences Nyon Vaud European...
13 KB (690 words) - 19:15, 2 November 2024
Alisporivir is under development by Debiopharm for Japan and by Novartis for the rest of the world (licence granted by Debiopharm) since February 2010.[citation...
7 KB (570 words) - 16:49, 4 February 2024
Balderton Capital and $2.7 million invested by the private equity arm of Debiopharm Group. Chief executive Stelio Tzonis said that use of the funding will...
4 KB (356 words) - 11:19, 23 April 2022
spin-off to date to emerge from PSI. In 2017, the Lausanne-based company Debiopharm licensed the active substance 177Lu-PSIG-2, which was developed at the...
49 KB (5,914 words) - 22:41, 10 November 2024
2024. Debiopharm Group Press Release (November 2010) "Abionic wins the 'Prix Debiopharm Valais pour les Sciences de la Vie", www.debiopharm.com "Abionic...
14 KB (1,246 words) - 22:58, 5 August 2024